January 24, 2023
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
October 26, 2021
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
August 17, 2021
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
No current content.
Connect with us LinkedIn